NEKTAR THERAPEUTICS

NKTR
Delayed Quote. Delayed  - 08/07 04:00:00 pm
21.85USD +1.58%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
Nektar Therapeutics specializes in the research and development of drugs for the treatment of cancer, autoimmune diseases and chronic pain. Net sales break down by source of income as follows:
- revenues from licensing and collaboration agreements (91.9%);
- product sales (4.6%);
- royalties (3.5%).
At the end of 2018, the Group had a portfolio of 11 products in clinical development (including 4 in phase III, 3 in phase II and 4 in phase I) and a product in pre-clinical development.
Net sales are distributed geographically as follows: the United States (91.4%) and Europe (8.6%).

Number of employees : 723 people.
Sales per Business
20182019
USD
(in Million)
%USD
(in Million)
%
Novel Drugs 1,193100% 114.62100%
Sales per region
2019
USD
(in Million)
%
Rest of World 87.5276.4%
United States 27.0923.6%
Managers
Name Title
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
Gilbert M. Labrucherie Senior VP, Chief Operating & Financial Officer
Jonathan Zalevsky Chief Research & Development Officer
Roy A. Whitfield Independent Director
Lutz Lingnau Independent Director
R. Scott Greer Independent Director
Jeffrey Robert Ajer Independent Director
Karin Eastham Independent Director
Myriam J. Curet Independent Director
Shareholders
Name Equities %
Invesco Advisers, Inc. 33,529,218 18.8%
PRIMECAP Management Co. 20,482,919 11.5%
Fidelity Management & Research Co. LLC 19,126,767 10.7%
OppenheimerFunds, Inc. 17,302,891 9.72%
The Vanguard Group, Inc. 16,261,055 9.14%
Wellington Management Co. LLP 15,746,960 8.85%
BlackRock Fund Advisors 5,575,112 3.13%
Maverick Capital Ltd. 4,898,401 2.75%
SSgA Funds Management, Inc. 4,631,555 2.60%
HealthCor Management LP 4,000,000 2.25%
Company contact information
455 Mission Bay Boulevard South
CA 94158 San Francisco, California
États-Unis (les)

Phone : +1 415 482 5300
Fax : +1 415 339 5300
Internet : https://www.nektar.com/
Markets and indexes
- Nasdaq Stock Market
- Nasdaq Global Select Market
- SP 500 /
Stock Exchange Codes
- Reuters Code :  NKTR.O
Sector Biotechnology & Medical Research - NEC
1st jan.Capi. (M$)
NEKTAR THERAPEUTICS1.23%3 829
LONZA GROUP60.76%46 341
CELLTRION, INC.73.76%35 071
IQVIA HOLDINGS INC.4.23%30 802
MODERNA, INC.277.10%28 680
SEATTLE GENETICS, INC.41.61%28 153
INCYTE CORPORATION11.80%21 268
ALNYLAM PHARMACEUTICALS, INC.25.14%16 625
GALAPAGOS NV-15.01%12 252
HANGZHOU TIGERMED CONSULTING CO.,LTD70.51%12 122
PHARMARON BEIJING CO., LTD.91.42%11 546
PPD, INC.0.00%11 071
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.42.58%10 820
QIAGEN N.V.38.67%10 717
BIO-TECHNE CORPORATION21.43%10 188
IMMUNOMEDICS, INC.104.06%9 981
ICON PUBLIC LIMITED COMPANY9.93%9 965
NOVAVAX, INC.4,108.54%8 622
IONIS PHARMACEUTICALS, INC.-6.46%7 894
PRA HEALTH SCIENCES, INC.-2.25%6 924
ACADIA PHARMACEUTICALS INC.1.99%6 880